EKF Lead Collaborator in Biomarkers of Progressive Diabetic Kidney Disease to Deliver Prestigious Kelly West Lecture at ADA Scientific Sessions for 2014

Dr. Andrzej Krolewski recognized for significant contribution to diabetes epidemiology

EKF Diagnostics, the global diagnostics company, today highlights that the lead scientist working in collaboration with its Kidney Biomarker team to develop tests for progressive Diabetic Kidney Disease (DKD) will receive the 2014 Kelly West Award in Epidemiology at the American Diabetes Association (ADA) 74th Scientific Sessions. Dr. Andrzej Krolewski, MD, PhD, Head of Section on Genetics and Epidemiology at the Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, receives this eminent award in recognition of his significant contribution to the field of diabetes epidemiology.

At the ADA 74th Scientific Sessions (13-17th June, 2014, San Francisco), Dr. Krolewski will also deliver the Kelly West Award lecture, ‘Time to Retire ‘Microalbuminuria’: Early, Progressive Renal Decline is the New Paradigm,’ (15th June, 2.15pm). “I am very pleased that I was selected to give the Kelly West Lecture,” said Dr. Krolewski. “This lecture will give me the opportunity to discuss important discoveries that we made in regard to diabetic kidney disease. Joslin is one of the best places to conduct this type of epidemiological research.”

Julian Baines, CEO, EKF Diagnostics, commented, “We offer our wholehearted congratulations to Dr. Andrzej Krolewski on his receipt of the Kelly West Award which is one of the ADA’s highest scientific awards. We look forward to continuing our partnership with him and his team as they continue to develop new models for management of Diabetic Kidney Disease and in particular, the role of biomarkers such as sTNFR1.”

On Stand 2321 at the ADA 74th Science Sessions, EKF Diagnostics will be exhibiting the first of its diagnostics tests for progressive DKD based on the sTNFR1 biomarker originally identified by Dr. Krolewski as a strong predictor of ESRD. Studies performed in multiple centers in US and Europe have shown that sTNFR1 outperforms current clinical tests in identifying high risk patients. EKF’s sTNFR1 test kit is an easy-to-use ELISA-based assay for which standard laboratory equipment and just 50 µL of blood serum or plasma are needed. The standard assay format means the test requires minimal training.

For more information on EKF Diagnostics, please click on the request information tab below or follow the company website link.